Interesting research from Bayer, as reported from Reuters:
Bayer’s Alzheimer’s disease (AD) marker florbetaben was shown to help detect the illness in eight out of 10 cases in a Phase II study, possibly offering a way to diagnose early onset. “(Bayer aims to) contribute to diagnosing AD in the future more precisely and at an earlier time during the course of the disease,” the company said in a statement on Sunday. – from Reuters